[ad_1]
Icon Plc (NASDAQ: ICLR) has received a consensual recommendation from "Buy" by the thirteen rating agencies that currently cover the company, Reports Marketbeat Two research badysts have badigned a pbading grade to the action, nine awarded a purchase grade and two awarded a strong rating to the company. $ 132.18
A number of brokerages have weighed on ICLR: BidaskClub has updated Icon shares, going from a "buy" note to a "strong buy" note in a research report on Friday 22 June. Credit Suisse Group raised its target price on Icon shares from $ 131.00 to $ 144.00, which earned it an overweight rating in a research report on Monday, June 18th. note in a research report on Tuesday 19 June. Zacks Investment Research upgraded Icon's shares from a "hold" rating to a "buy" rating and set a target price of $ 147.00 for the company in a published research report Thursday. Finally, Jefferies Financial Group increased its target price on Icon shares to $ 150.00 and awarded the title a purchase note in a research report on Friday, June 1.
Icon fell $ 0.19, to $ 132.43, reports Tuesday Marketbeat. 2,000 shares of the company were traded for an average volume of 187,458. The company has a ratio of 1.85, a ratio of 1.85 and a debt ratio of 0.29. The company has a market capitalization of $ 7.15 billion, a capitalization ratio of 24.80, a price / earnings ratio of 2.07 and a beta of 0.45. Icon has a 52-week low of $ 96.03 and a high of $ 52 from $ 138.17.
Icon (NASDAQ: ICLR) released its financial results for the last time on Thursday, May 3rd. The medical research company reported $ 1.42 of earnings per share for the quarter, leading consensus badyst estimates of $ 1.41 per $ 0.01. The company achieved a turnover of $ 620.13 million during the quarter, compared with $ 562.61 million for badysts. Icon has a net margin of 14.80% and a return on equity of 26.56%. The quarterly business figure of the company rose 43.6% from one year to the next. During the same quarter last year, the company posted earnings per share of $ 1.29. Analysts expect Icon to post earnings per share of 6.05 for the current fiscal year.
Hedge funds have recently added or reduced their holdings in the company. Financial Gravity Wealth Inc. has purchased a new position in Icon shares in the first quarter worth approximately $ 179,000. Gotham Asset Management LLC purchased a new stake in Icon in the fourth quarter, valued at approximately $ 209,000. We Are One Seven LLC has purchased a new stake in Icon in the fourth quarter, valued at approximately $ 252,000. First National Bank of Omaha bought a new stake in Icon in the first quarter valued at about $ 279,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in Icon in the first quarter, valued at approximately $ 296,000. Institutional investors own 87.14% of the shares of the company.
About Icon
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical industries in Ireland, Europe, United States and Europe. internationally. He specializes in the strategic development, management and badysis of programs that support various stages of the clinical development process from compound selection to phase I to IV clinical studies
Receive news and rating for Icon Daily – Enter your email address below to receive a daily concise summary of the latest news and badyst ratings for Icon and related companies with FREE MarketBeat.com Daily E-newsletter.
Source link
